1. Introduction {#sec1}
===============

Cholangiocarcinoma (CCA) is a primary liver cancer with features of differentiation of cholangiocytes, the epithelial cells lining the intra- and extrahepatic portions of the biliary tree \[[@B1]\]. An increasing incidence of CCA has been reported over the last few decades \[[@B2]\]. It is the second most frequent type of primary liver cancer and comprises malignancies with high inter- and intratumor heterogeneities. It is currently classified into intrahepatic, perihilar, and distal extrahepatic cholangiocarcinoma \[[@B3]\]. Surgical resection remains the best therapeutic approach for CCA, but unfortunately most patients are diagnosed at an unresectable stage of the disease. Although the accuracy of current diagnostic methods has greatly improved, the 5-year overall survival (OS) remains poor \[[@B4], [@B5]\]. Therefore, a reliable and readily accessible preoperative prognostic biomarker is required to determine the optimal therapeutic strategies.

A growing number of studies have shown that cancer-related inflammation results in poor prognosis. Moreover, inflammation plays a strong role in tumor development, progression, and metastasis \[[@B6]\]. Accordingly, inflammation-based prognostic indicators, such as the Glasgow prognostic score (GPS), C-reactive protein (CRP), and neutrophil-to-lymphocyte ratio (NLR), have been investigated in various cancers \[[@B7]--[@B9]\]. The NLR has been associated with worse prognosis in various cancers \[[@B10]--[@B12]\]. However, because of the inconsistent results, whether PLR is associated with the prognosis in CCA remains controversial \[[@B13]--[@B15]\]. We therefore conducted a meta-analysis to assess the prognostic role of PLR and analyze the relationships between PLR and clinicopathological parameters in patients with CCA.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategies {#sec2.1}
----------------------

A systematic search of electronic databases, including MEDLINE, EMBASE, and Cochrane Library, was performed up to August 5, 2018, to obtain relevant articles for the meta-analysis. Studies were selected using the following key words: "cholangiocarcinoma" or "bile duct cancer" and "tumor" or "cancer" or "neoplasm" or "carcinoma" or "malignancy" and "platelet lymphocyte ratio" or "PLR". Other relevant studies were also obtained by manually screening the references list.

2.2. Selection Criteria {#sec2.2}
-----------------------

The inclusion criteria were as follows: (1) studies investigate the PLR and survival in CCA; (2) CCA was confirmed by pathological examination; (3) the HR and 95% CI, or Kaplan--Meier survival curves from which an HR could be calculated, were reported; and (4) a cut-off value for PLR was reported. The exclusion criteria were as follows: (1) reviews, letters, or conference abstracts; (2) insufficient data or unavailable data; and (3) studies with duplicate data.

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

Two investigators (G.H. and Q.L.) performed the data extraction independently. Data were extracted as follows: first author\'s name, publication year, country, number of patients, follow-up period, treatment, gender, age, CA199, differentiation, lymph node metastasis, vascular invasion, postoperative complication, postoperative mortality, margin status, survival analysis methods, HR estimate, and cut-off values. Margin status included R0 (microscopically negative resection margins) and R1 (microscopically positive resection margins).

The methodological quality of included studies was independently assessed by two independent reviewers (G.H. and Q.L.) according to the Newcastle-Ottawa Scale (NOS) \[[@B16]\], which included three primary domains: selection, comparability, and outcome. Studies with an NOS score of *⩾*6 were deemed high-quality studies. Any discrepancy was resolved by joint discussion.

2.4. Statistical Analysis {#sec2.4}
-------------------------

We used Stata 13.0 statistical software (Stata, College Station) to estimate HRs for OS, PFS, and RFS and odd ratios (ORs) for clinicopathological parameters. If the statistical variables were described in the study, we extracted them directly. Otherwise, they were calculated with Kaplan-Meier survival curves, which were read according to the methods described by Tierney et al. and Parmar \[[@B17], [@B18]\]. The heterogeneity among the studies was evaluated by the chi-square value and the I^2^ value. If I^2^ ⩽ 50% or P \> 0.05, a fixed-effects model was used for analysis. If not (I^2^ \> 50% or P ⩽ 0.05), a random-effects model was used. We then performed subgroup analyses to examine the potential source of heterogeneity. To validate the credibility of the result, sensitivity analyses were performed by removing each study. A P value less than 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Study Characteristics {#sec3.1}
--------------------------

As shown in the flow diagram ([Figure 1](#fig1){ref-type="fig"}), 111 potentially relevant articles were obtained through electronic searches. 99 articles remained after exclusion of duplicated data. After screening the titles and abstracts carefully, 75 articles were excluded. Finally, a total of 9 studies were included in the meta-analysis \[[@B13]--[@B15], [@B19]--[@B24]\]. All of the included studies were retrospective observational cohorts. Most of these studies have been published since 2017. Of the 9 studies, four studies were from China, three were from Japan, one was from Korea, and one was from multiple centers. The treatments were surgery and mixed methods. All studies assessed the association between pretreatment PLR and OS, whereas 4 studies reported RFS or PFS. Cut-off values of PLR ranged from 123 to 190. The main characteristics of the 9 enrolled studies are shown in [Table 1](#tab1){ref-type="table"}. NOS scores of all the studies were at least 6 or more ([Table 2](#tab2){ref-type="table"}).

3.2. Meta-Analysis {#sec3.2}
------------------

### 3.2.1. Impact of PLR on OS {#sec3.2.1}

Nine studies, comprising 2395 patients, reported the relationship between PLR and OS. The HR, expressed as the high-PLR group versus the low-PLR group, was 1.00 (95% CI = 1.00-1.00, P = 0.085). Buettner et al.\'s study was not included in this meta-analysis of OS. The pooled result showed that patients with high PLR had a worse OS (HR: 1.38, 95% CI: 1.19-1.62, P \< 0.001), with no heterogeneity (I^2^= 16.5%, P = 0.30; [Figure 2](#fig2){ref-type="fig"}). The association between PLR and OS was further evaluated by subgroup analysis based on the main features, including tumor stage, cut-off for PLR, treatment, and analysis method ([Table 3](#tab3){ref-type="table"}). The results indicated that elevated PLR significantly predicted shorter OS in patients who received surgery (HR = 1.43; 95% CI = 1.12-1.83; P = 0.005) or mixed treatments (HR = 1.89; 95% CI = 1.11-3.14; P = 0.020). When stratified by disease stage, PLR was a prognostic factor in patients with mixed stages (HR = 1.40; 95% CI = 1.18-1.67; P \< 0.001). Pooled HRs for OS were stratified by HR analysis methods. The negative effect of elevated PLR on OS was observed by multivariate analysis (HR = 1.52; 95% CI = 1.27-1.81; P \< 0.001). Moreover, PLR showed prognostic value regardless of the cut-off value for NLR (*⩾* 150 and \< 150).

### 3.2.2. Impact of PLR on PFS/RFS {#sec3.2.2}

Four studies were included in the analysis of PLR and PFS/RFS. The pooled HR was 1.55, which indicated that elevated PLR was significantly associated with poor PFS/RFS ([Figure 3](#fig3){ref-type="fig"}). There was no significant heterogeneity between the included studies (I^2^ = 19.0%; P = 0.295).

### 3.2.3. Associations between PLR and Clinicopathological Parameters {#sec3.2.3}

To further exploit the impact of PLR on clinicopathological features, we identified 9 clinicopathological parameters ([Table 4](#tab4){ref-type="table"}). As shown in [Table 3](#tab3){ref-type="table"}, the results demonstrated that elevated PLR was highly correlated with gender (male versus female; OR = 0.59, 95% CI: 0.44-0.80, P \< 0.001) and margin status (R1 versus R0; OR = 2.09, 95% CI: 1.24-3.54, P = 0.006). However, elevated PLR was not related to age (*⩾* 45 versus \< 45; OR = 0.82, 95% CI: 0.38-1.77, P = 0.61), CA199 (\>37 ng/mL versus \<37 ng/mL; OR = 1.25, 95% CI: 0.92-1.70, P = 0.16), differentiation (low versus moderate/high; OR = 1.05, 95% CI: 0.64-1.73, P = 0.85), lymph node metastasis (pos versus neg; OR = 1.16, 95% CI: 0.82-1.65, P = 0.39), vascular invasion (pos versus neg; OR = 1.27, 95% CI: 0.86-1.89, P = 0.23), postoperative complications (present versus absent; OR = 1.44, 95% CI: 0.97-2.14, P = 0.07), and postoperative mortality (present versus absent; OR = 1.54, 95% CI: 0.56-4.26, P = 0.41).

3.3. Sensitivity Analysis {#sec3.3}
-------------------------

Sensitivity analysis was performed to assess the stability of the results. The result was not significantly impacted by removing any eligible study ([Figure 4](#fig4){ref-type="fig"}).

4. Discussion {#sec4}
=============

In this study, a meta-analysis was conducted to investigate the correlations between pretreatment PLR and clinicopathological characteristics and to evaluate the prognostic value of PLR in patients with CCA. The combined results demonstrated that elevated PLR is significantly associated with worse OS and RFS/PFS. Therefore, PLR could serve as biomarker for the prognosis of CCA patients. Additionally, the correlations between PLR and clinicopathological parameters were evaluated. Elevated PLR was correlated with female sex and margin status (R1).

The exact mechanisms by which PLR predicts poor outcome of CCA patients are still undefined. Emerging evidence has indicated strong linkage between systemic inflammatory response and tumor development \[[@B6], [@B25], [@B26]\]. Platelets, as a participant in the inflammatory response, protect tumor cells from natural killer-mediated lysis, thus supporting the tumor metastasis \[[@B27]\]. A variety of platelet-associated chemokines can modulate inflammation within the tumor environment and tumor angiogenesis, such as platelet factor 4 (PF-4/CXCL4) and connective tissue-activating peptide III (CTAP-III) \[[@B28]\]. Lymphocytes play a major role in suppressing cancer cell proliferation and migration \[[@B29]\]. Tumor-infiltrating lymphocytes (TILs) are vital components of the antitumor immune microenvironment and are involved in several stages of tumor progression \[[@B30], [@B31]\]. Tumor-infiltrating CD8+ and CD4+ T lymphocytes induce cytotoxic cell death and inhibit tumor cell proliferation and migration in antitumor immune reactions \[[@B32], [@B33]\]. Conversely, low lymphocyte counts may lead to inadequate immune responses, resulting in poor survival of many cancers \[[@B34], [@B35]\]. Thus, PLR may represent a balance between the tumor promotion reaction and antitumor immune function.

Several limitations should be taken into consideration when interpreting our findings. First, the cut-off value of PLR applied in the enrolled studies was not uniform. Second, all of the included studies were retrospective and published in English. Third, this meta-analysis is not registered online. Fourth, all included studies were from Asia, which means that our data do not represent the CCA picture globally. It remains unclear whether these findings might be applied to other populations. Therefore, more large-scale studies are warranted to assess the prognostic value of pretreatment PLR for cervical cancer patients.

5. Conclusions {#sec5}
==============

Our meta-analysis confirmed that elevated pretreatment PLR is associated with poor prognosis in patients with CCA. Therefore, PLR may serve as a promising biomarker for predicting prognosis in patients with CCA.
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###### 

Characteristics of the studies included in the meta-analysis.

  Author     Year   Area          Follow-up (months)   Treatment      No. of patients   Stage        Cut-off value   Survival analysis   Analysis
  ---------- ------ ------------- -------------------- -------------- ----------------- ------------ --------------- ------------------- ----------
  Buettner   2018   Multicenter   29 (4.8-53.3)        Surgery        991               NA           190             OS                  UV
  Chen       2015   China         57.8±11.2            Surgery        322               Mixed        123             OS/RFS              MV
  Cho        2018   Korea         25 (19.6-30.4))      Chemotherapy   257               Metastatic   123.8           OS/PFS              UV
  Hu         2018   China         NA                   Surgery        173               Mixed        150             OS                  UV
  Kitano     2017   Japan         NA                   Mixed          120               Mixed        185             OS/RFS              MV
  Ramen      2018   China         NA                   Surgery        90                NA           148             OS/RFS              MV
  Saito      2015   Japan         70 (42-82)           Surgery        121               Mixed        150             OS                  MV
  Yoh        2017   Japan         65 (26-84)           Surgery        134               Mixed        120             OS                  MV
  Zhang      2016   China         NA                   NA             187               Mixed        138             OS                  MV

OS: overall survival; PFS: progress-free survival; RFS: recurrence-free survival; UV: univariate; MV: multivariate; NA: not available.

###### 

Assessment of study quality.

  Author     Selection   Comparability   Outcome   Total score
  ---------- ----------- --------------- --------- -------------
  Buettner   ★★★★        ★★              ★★★       9
  Chen       ★★★★        ★★              ★★        8
  Cho        ★★★★        ★★              ★★        8
  Hu         ★★★         ★               ★★        6
  Kitano     ★★★★        ★               ★         6
  Ramen      ★★★         ★★              ★★★       8
  Saito      ★★★★        ★               ★         6
  Yoh        ★★★★        ★               ★★        7
  Zhang      ★★★★        ★               ★         6

###### 

Pooled hazard ratios (HRs) for OS according to subgroup analyses.

  Subgroup             No. of studies   No. of patients   HR (95% CI)        P value   Heterogeneity   
  -------------------- ---------------- ----------------- ------------------ --------- --------------- -------
  Overall              8                1404              1.38 (1.19-1.62)   \<0.001   16.5            0.30
  Treatment                                                                                             
   Surgery             5                840               1.43 (1.12-1.83)   0.005     30.8            0.22
   Chemoradiotherapy   1                257               1.19 (0.91-1.55)   0.200     ---             ---
   Mixed               1                120               1.89 (1.11-3.14)   0.020     ---             ---
  Stage                                                                                                 
   Mixed               6                866               1.40 (1.18-1.67)   \<0.001   8.2             0.36
   Metastatic          1                257               1.19 (0.91-1.55)   0.200     ---             ---
  Cut-off                                                                                               
   ≥150                3                485               1.59 (1.03-2.46)   0.036     56.2            0.102
   \<150               5                919               1.33 (1.14-1.56)   \<0.001   0               0.505
  Analysis method                                                                                       
   Univariate          2                430               1.16 (0.93-1.45)   0.174     0               0.778
   Multivariate        6                974               1.52 (1.27-1.81)   \<0.001   0               0.426

###### 

Meta-analysis of the association between PLR and clinicopathological features of CCA.

  Characteristics                                   No. of studies   No. of patients   OR (95% CI)        p          Heterogeneity   
  ------------------------------------------------- ---------------- ----------------- ------------------ ---------- --------------- ------
  Age (≥ median vs. \< median)                      3                669               0.82 (0.38-1.77)   0.61       70              0.03
  Gender (male vs. female)                          4                789               0.59 (0.44-0.80)   \< 0.001   0               0.94
  CA199 (\>37 ng/mL vs. \<37 ng/mL)                 3                669               1.25 (0.92-1.70)   0.16       0               0.56
  Differentiation (low vs. moderate/high)           2                442               1.05 (0.64-1.73)   0.85       0               0.90
  Lymph node metastasis (pos vs. neg)               4                1194              1.16 (0.82-1.65)   0.39       0               0.63
  Vascular invasion (pos vs. neg)                   2                978               1.27 (0.86-1.89)   0.23       0               0.56
  Postoperative complication (present vs. absent)   2                776               1.44 (0.97-2.14)   0.07       0               0.39
  Postoperative mortality (present vs. absent)      2                776               1.54 (0.56-4.26)   0.41       0               0.67
  Margin status (R1 vs. R0)                         2                776               2.09 (1.24-3.54)   0.006      0               0.69

R0: microscopically negative resection margins; R1: microscopically positive resection margins.
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